| Dear Voornaam,
Welcome to your weekly Cancer Research UK Research Update email.
Women face barriers in the workplace that are not unique to academia. That’s why we pair female scientists with leading businesswomen through our Women of Influence mentoring scheme. These mentors provide support and advice on tackling common challenges in areas such as management, confidence and work-life balance.
We’re currently seeking applications from new mentors from diverse backgrounds and geographical locations across a range of professional sectors. Could you be a mentor? Or do you know someone who might want to get involved?
Help empower the next generation of female cancer research leaders by spreading the word about this opportunity. Contact the Women of Influence team to join or support the programme. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
 |
NEW PODCAST EPISODE WITH PROFESSOR CHARLES SWANTON To mark the beginning of Lung Cancer Awareness Month, our latest episode of our Cancer Research Matters podcast features our chief clinician, Professor Charles Swanton.
Ten years ago, lung cancer-specific research was still limited, despite lung cancer being the most common cause of cancer death in the UK. In 2014 we took the decision to make lung cancer a strategic priority and made our biggest investment in lung cancer to date – the TRACERx study.
TRACERx is the largest and most detailed genetic study of its kind in lung cancer. It has unveiled new insights into how lung cancer evolves over time, laying the foundations for diagnosis and treatment. TRACERx has also helped build a lung cancer research community and fostered the early careers of clinical and non-clinical researchers. It has generated an unrivalled dataset that is used around the world and is sparking collaborations that are shaking up the research and clinical landscape in lung cancer and beyond. Scientific discoveries stemming from TRACERx have led to several spin-out companies, including Achilles, which are helping to translate these discoveries into clinical applications.
Listen to the episode to hear Charlie discuss the changing field of lung cancer research, the far-reaching impact of TRACERx, and what this means for patients. |
|
|---|
|
|---|
|
|
A NEW TOOL TO MATCH PATIENTS TO TRIALS Finding suitable, increasingly stratified clinical trials for patients can be challenging and time-consuming.
A new search tool is now available to make it quicker and easier to match patients to early-phase cancer trials within the ECMC network – and it is open to all clinical staff in the UK.
The Experimental Cancer Trial Finder enables clinicians to search for trials using select patient eligibility criteria including age, location, molecular markers, and treatment types. All trial information is updated monthly, and with closed access for clinicians, it includes the contact details of all actively recruiting sites for easier, faster patient referral. |
|
|---|
|
|---|
|
|
 BRINGING BIOLOGY TO PREVENTION RESEARCH WEBINAR Reserve your spot in our upcoming webinar and join Professors Kay-Tee Khaw and Karen Brown (Chair and Vice-chair of our Prevention and Population Research Committee), and Dave Crosby (Head of Prevention and Early Detection Research), as they share everything you need to know about our new Biology to Prevention Award.
With this award we’re supporting interdisciplinary, innovative approaches to prevention research with up to £600k of funding.
Join us at 2pm GMT on 23 November for a panel discussion to address your questions on this new funding and what makes a successful application. |
|
|---|
|  CANTEST PRIMARY CARE CANCER DETECTION SUMMIT The CanTest Collaborative, funded by a Cancer Research UK Catalyst Award, is now in its fifth and final year. We're celebrating its research achievements in early detection and diagnosis at the Primary Care Cancer Detection Summit in London on 14–15 November.
Experts from across a range of disciplines will discuss cancer detection in primary care, improvement opportunities in the field, and recent clinical and policy changes. There will also be ample opportunity for networking – speakers include our CEO Michelle Mitchell OBE and Professors Sir Mike Richards, Larry Kessler, and Peter Johnson CBE. |
|
|---|
|
|---|
|
|
 NEW IN NATURE: MUTATIONAL PATTERNS IN BREAST AND OVARIAN CANCERS Researchers from the Cancer Grand Challenges IMAXT team at the Aparicio lab at BC Cancer Research have identified three distinct mutational patterns in triple negative breast and high grade serous ovarian cancers.
Their findings show that the patterns contribute to phenotypic and evolutionary diversity in these cancers and provide insight into the genomic and mutational states of individual cancer cells.
This has important implications for therapies targeting frequently altered oncogenes particularly in cancer types with high genomic instability. Especially because these are more likely to develop treatment-resistant clones. |
|
|---|
|  DIRECTOR’S LECTURE WITH PROFESSOR KAREN KNUDSEN Professor Karen Knudsen, Chief Executive Officer of the American Cancer Society, will speak about the latest efforts of the American Cancer Society at the Manchester Cancer Research Centre on 4 November.
Karen will discuss the American Cancer Society's work on reducing the burden of cancer and enhancing health equity through research, advocacy and patient support, and the opportunities for collaboration and partnership.
Join the lecture at 3.30pm GMT on 4 November in-person from the Oglesby Cancer Research Building in Manchester or over Zoom. |
|
|---|
|
|---|
|
|
ACCESS STATE-OF-THE-ART CRISPR TECHNOLOGY If your research could benefit from CRISPR technology, Cancer Research Horizons are keen to work with you to progress your research.
By running pooled CRISPR screens they can help you identify and validate new drug targets and approaches to benefit cancer patients. The team can also support you in planning your project to give you the best opportunity for success, while you maintain researcher autonomy.
Submit your proposal to the Cancer Research Horizons-Astrazeneca Functional Genomic Centre by 15 November. |
|
|---|
|
|---|
|
|
| | | London, UK 14 November 2022 |
|
|---|
|
|---|
| | | Manchester, UK 15 November 2022 |
|
|---|
|
|---|
| | | Online 2:00 PM 23 November 2022 |
|
|---|
|
|---|
| | | East Sussex, UK 04 December 2022 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
